Latest News and Press Releases

London, UK, Boston, MA, 20 August 2026 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today announced that data on...

Here are today’s catalysts reshaping the market narrative for $NTHI, $IPST, $OABI, $LLY

Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center...

NeOnc (NASDAQ:NTHI) heads into Wednesday with a special setup that can put a clinical-stage biotech squarely on the market’s radar

New 23andMe study of 114,000+ people links CYP2C19 gene variants to SSRI side effects like sexual dysfunction and poor sleep.

New preclinical data demonstrate that SIL204 treatment produced statistically significant upregulation of FAS (CD95), the immune “death receptor,” and statistically significant downregulation of...

Vantage Biosciences completes enrollment in the Phase 2 SeeClear study of oral oruvestat in non-proliferative diabetic retinopathy.

Splash expands its exclusive global license for CannEpil® to include veterinary applications, creating a second regulated pharmaceutical development platfo

Noom Health is partnering with Levrx to optimize metabolic health/ GLP-1 programs directly through existing pharmacy benefit platforms

Successful initiation of the Phase 2/3 clinical trial of SIL204 at Tel Aviv Sourasky Medical Center (“TASMC” or “Ichilov”), one of Israel’s largest and most prominent academic medical centers, clears...